Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 695M P/E - EPS this Y -16.20% Ern Qtrly Grth -
Income -35.59M Forward P/E -10.52 EPS next Y -39.20% 50D Avg Chg 8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 30.00%
Dividend N/A Price/Book 2.87 EPS next 5Y - 52W High Chg -23.00%
Recommedations 1.80 Quick Ratio 24.14 Shares Outstanding 52.03M 52W Low Chg 134.00%
Insider Own 40.39% ROA -10.72% Shares Float 7.49M Beta 0.80
Inst Own 58.01% ROE -15.18% Shares Shorted/Prior 1.48M/1.31M Price 13.36
Gross Margin - Profit Margin - Avg. Volume 63,217 Target Price 32.00
Oper. Margin - Earnings Date - Volume 54,831 Change -5.58%
About GH Research PLC

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC News
05/13/24 Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
05/10/24 Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
05/03/24 GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
03/05/24 How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
02/29/24 GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
01/18/24 GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
01/16/24 Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
12/29/23 11 Best Psychedelic Stocks to Buy in 2024
12/25/23 We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
12/20/23 11 Most Promising Psychedelic Stocks According to Hedge Funds
12/19/23 15 Best Falling Stocks To Buy Now
11/09/23 GH Research Reports Third Quarter Financial Results and Provides Business Updates
09/29/23 GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
08/23/23 GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
10:53 AM Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation
07/06/23 ‘It’s Really a Brain Chemistry Issue’: Elon Musk Embraces Ketamine in the Battle Against Depression — Here Are 2 Psychedelic Stocks That Analysts Like
06/29/23 The 3 Best Psychedelic Stocks to Buy Now
GHRS Chatroom

User Image AnomalyDetective Posted - 2 days ago

$LABU #biotech breakout continues in bullish stair steps as #CPI delivers better than expected inflation data. Many prior MDA biotech selections moving higher: $CDXS $GHRS $THRD $VYGR www.vmbreakouts.com

User Image havacubepunch Posted - 1 week ago

$GHRS beast

User Image PsychedStocks Posted - 1 week ago

$CYBN $MNMD $ATAI $GHRS $SPY Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones. https://ir.cybin.com/investors/news/news-details/2024/Cybin-Provides-Corporate-Update-and-Highlights-Upcoming-Clinical-Milestones/default.aspx

User Image DonCorleone77 Posted - 2 weeks ago

$GHRS GH Research reports Q1 EPS (15c), consensus (22c) Cash, cash equivalents, other financial assets and marketable securities were $214.0 million as of March 31, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023. Other financial assets are comprised of money market funds, and marketable securities are comprised of investment grade bonds. The company believes that existing cash, cash equivalents, other financial assets and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2026.

User Image Stock_Titan Posted - 2 weeks ago

$GHRS GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates https://www.stocktitan.net/news/GHRS/gh-research-reports-first-quarter-2024-financial-results-and-9snqitd4enxy.html

User Image eloquence Posted - 04/29/24

$MNMD $CYBN $CMPS $GHRS $ATAI Investing Across the Psychedelic Medicine Ecosystem: An Interview with Cody Shandraw https://youtu.be/c0q6sboP97s

User Image CK66 Posted - 04/25/24

$GHRS Why average PT around $31. Is that real? Haven't see a PT lower than $18 anywhere??

User Image havacubepunch Posted - 04/25/24

$GHRS BEAST

User Image Doozio Posted - 1 month ago

$GHRS chop chop huckleberries…. 🧠⏰. Barring a faatch 💣

User Image eloquence Posted - 03/27/24

$ATAI $MNMD $GHRS $CYBN $CMPS Psychedelic Vantage - Psychedelic Stock Portfolio Updates Podcast Episode - https://youtu.be/GoWjYUpHpIk?si=TILcrRF2-UwGjUsE

User Image eloquence Posted - 03/26/24

$ATAI $MNMD $CYBN $CMPS $GHRS Psychedelic Vantage - Psychedelic Stock Portfolio Updates https://youtu.be/GoWjYUpHpIk?si=5YC7eSEr-sXmqQ52

User Image CK66 Posted - 03/26/24

$GHRS Haven't seen any words of wisdom about GHRS lately. Anybody smarter than me have any thoughts? In at $8.50. PT still around $34

User Image havacubepunch Posted - 2 months ago

$GHRS amazing

User Image PsychedStocks Posted - 2 months ago

$CYBN amazing news!!! Exactly what we were hoping for with FDA Breakthrough Therapy Designation for CYB003 and US $150 million from institutional investors! The company won't need to raise money again for completing all phases of clinical trials of CYB003 and CYB004 $MNMD $ATAI $CMPS $GHRS

User Image _www_larval_com_ Posted - 2 months ago

$HNRA -7%[120%] $NKGN -7%[-33%] $GHRS 3%[11%] most notable movement into the final minutes of trading.

User Image eloquence Posted - 2 months ago

$MNMD $GHRS $ATAI $CYBN $CMPS In this episode, we go over the results from Mindmeds most recent trial. https://youtu.be/L2pv_2eLZ6E?si=hdDmHNp6q9-h-5LW

User Image TalkMarkets Posted - 2 months ago

#Psychedelic Compound-Based Drug Stock, #MindMedicine, Up 56% Last Week $ATAI $MNMD $CMPS $GHRS $IXHL https://talkmarkets.com/content/stocks--equities/psychedelic-compound-based-drug-stock-mind-medicine-up-56-last-week?post=436084

User Image eloquence Posted - 2 months ago

$MNMD $CMPS $IXHL $GHRS $ATAI Psychedelic Sector Weekly Recap - https://youtu.be/je-QwCU4AZU?si=TXgR5Erzbl-d0Efy

User Image TalkMarkets Posted - 2 months ago

Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD $ATAI $MNMD $CMPS $GHRS $IXHL https://talkmarkets.com/content/stocks--equities/largest-psychedelic-compound-based-drug-stocks-up-15-in-february-now-up-33-ytd?post=434574

User Image AnaChart Posted - 2 months ago

$GHRS https://anachart.com/wp-content/uploads/ana_temp/1709312544_soc-img.jpg

User Image DonCorleone77 Posted - 02/29/24

$GHRS GH Research reports FY23 EPS (68c), consensus (67c) The company said, "Cash, cash equivalents, other financial assets and marketable securities were $222.7 million as of December 31, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Other financial assets are comprised of money market funds, and marketable securities are comprised of investment grade bonds. We believe that our existing cash, cash equivalents, other financial assets and marketable securities will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2026."

User Image Stock_Titan Posted - 02/29/24

$GHRS GH Research Reports Full Year 2023 Financial Results and Provides Business Updates https://www.stocktitan.net/news/GHRS/gh-research-reports-full-year-2023-financial-results-and-provides-jpoxh8nfnwqj.html

User Image hbwalk2 Posted - 02/27/24

$GHRS Getting ready to sprout its wings.

User Image PsychedStocks Posted - 02/27/24

$CYBN $CMPS $ATAI $GHRS $NVDA Cybin to Present at the TD Cowen 44th Annual Health Care Conference https://ir.cybin.com/investors/news/news-details/2024/Cybin-to-Present-at-the-TD-Cowen-44th-Annual-Health-Care-Conference/default.aspx

User Image havacubepunch Posted - 02/22/24

$GHRS bought more. Started at 5.50

User Image PsychedStocks Posted - 3 months ago

$CYBN $CMPS $ATAI $PFE $GHRS Cybin Reports Third Quarter Financial Results and Recent Business Highlights https://ir.cybin.com/investors/news/news-details/2024/Cybin-Reports-Third-Quarter-Financial-Results-and-Recent-Business-Highlights/default.aspx

User Image havacubepunch Posted - 3 months ago

$GHRS sell off ? Lol

User Image kaylafinn Posted - 01/31/24

$GHRS Nice selloff

User Image havacubepunch Posted - 01/31/24

$GHRS I love this stock

User Image havacubepunch Posted - 01/30/24

@TradeAnimal2020 $GHRS

Analyst Ratings
HC Wainwright & Co. Buy May 7, 24
Canaccord Genuity Buy May 6, 24
HC Wainwright & Co. Buy Mar 4, 24
JMP Securities Market Outperform Mar 1, 24
HC Wainwright & Co. Buy Jan 18, 24
HC Wainwright & Co. Buy Nov 14, 23
HC Wainwright & Co. Buy Jul 6, 23
HC Wainwright & Co. Buy May 12, 23
JMP Securities Outperform May 12, 23